Fragile X syndrome: From protein function to therapy

Area of Science:

• Genetics and Neurodevelopmental Disorders
• Molecular Biology and Gene Regulation

Background:

• Fragile X syndrome (FXS) is the primary monogenic cause of intellectual disability and autism spectrum disorder.
• FXS results from instability in the CGG repeat within the FMR1 gene, leading to gene silencing and loss of the fragile X mental retardation protein (FMRP).

Purpose of the Study:

• To review the current understanding of FMRP function in relation to FXS.
• To provide an overview of therapeutic strategies developed for FXS, including those tested in animal models.

Main Methods:

• Literature review of existing research on FMRP function and FXS.
• Analysis of therapeutic strategies and their efficacy in preclinical models.

Main Results:

• FMRP plays crucial roles in mRNA transport to synapses and regulates the translation and stability of specific mRNAs.
• Dysregulation of FMRP targets is a key mechanism contributing to FXS pathology.
• Knowledge of FMRP's function has guided the development of potential therapeutic interventions.

Conclusions:

• FMRP's multifaceted roles in gene expression regulation are central to understanding FXS.
• Targeting FMRP pathways offers promising therapeutic avenues for FXS, with ongoing research in both animal models and human studies.